niacinamide has been researched along with Sarcoma in 29 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Additional clinical trials further exploring sorafenib as a treatment of locally advanced or metastatic chordomas are warranted." | 9.20 | Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). ( Amela, EY; Bertucci, F; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Collard, O; Isambert, N; Italiano, A; Laurence, V; Le Cesne, A; Lebellec, L; Penel, N; Saada-Bouzid, E; Salas, S; Tresch-Bruneel, E, 2015) |
| "This phase I trial assessed safety, pharmacokinetics (PK), dose limiting toxicity (DLT), maximum tolerated dose and recommended dose (RD) of the combination of sorafenib plus ifosfamide in patients with advanced sarcoma." | 9.19 | Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. ( Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM, 2014) |
| "We conducted a phase I trial of the addition of sorafenib to a chemoradiotherapy regimen in patients with high-risk (intermediate/high grade, >5 cm) extremity soft tissue sarcoma undergoing limb salvage surgery." | 9.17 | Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. ( Afzal, A; Beckett, BR; Doung, YC; Hayden, JB; Holtorf, ML; Huang, W; Hung, AY; Jones, RL; Mansoor, A; Meyer, JM; Mori, M; Perlewitz, KS; Pommier, RF; Rodler, ET; Ryan, CW; Tudorica, A; Vetto, JT; Woodward, WJ, 2013) |
| "To report on the anti-tumour activity and toxicity of sorafenib combined with dacarbazine in patients with pre-treated advanced soft tissue sarcoma (STSs)." | 9.17 | Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. ( Dei Tos, AP; Del Vescovo, R; Frezza, AM; Santini, D; Schiavon, G; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB, 2013) |
| "Sorafenib appears to be a promising option in leiomyosarcoma patients." | 9.17 | Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. ( Basso, U; Bertuzzi, A; Boglione, A; Comandone, A; De Sanctis, R; Giordano, L; Lutman, FR; Marcon, I; Santoro, A; Soto Parra, H; Stroppa, E, 2013) |
| "The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease." | 9.16 | Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. ( Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M, 2012) |
| "Phase II multi-disease randomized discontinuation trial to assess the safety and efficacy of sorafenib including patients with advanced soft tissue sarcoma (STS)." | 9.15 | Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. ( Cupit, L; Flaherty, KT; Judson, IR; Kaye, SB; O'Dwyer, PJ; Pacey, S; Ratain, MJ; Rowinsky, EK; Xia, C, 2011) |
| "PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic sarcoma." | 9.14 | Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. ( Antonescu, CR; Blachère, NE; Brockstein, B; Cooney, MM; D'Adamo, DR; Edgar, MA; Elias, AD; Hensley, ML; Keohan, ML; Kraft, AS; Livingston, MB; Maki, RG; Mita, MM; Qin, LX; Saulle, M; Schuetze, SM; Schwartz, GK; Schwartz, LH; Takimoto, CH; Undevia, SD, 2009) |
| "Sorafenib was continued during the entire period of RT as tolerated." | 6.79 | Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. ( Borys, D; Boutin, RD; Canter, RJ; Christensen, SD; Lee, LY; Li, CS; Monjazeb, AM; Olusanya, A; Tamurian, RM, 2014) |
| "Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies." | 6.77 | Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). ( Ancukiewicz, M; Boucher, Y; Demetri, GD; Duda, DG; Eder, JP; Jain, RK; Lahdenranta, J; Morgan, JA; Quek, R; Raut, CP, 2012) |
| "Additional clinical trials further exploring sorafenib as a treatment of locally advanced or metastatic chordomas are warranted." | 5.20 | Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). ( Amela, EY; Bertucci, F; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Collard, O; Isambert, N; Italiano, A; Laurence, V; Le Cesne, A; Lebellec, L; Penel, N; Saada-Bouzid, E; Salas, S; Tresch-Bruneel, E, 2015) |
| "This phase I trial assessed safety, pharmacokinetics (PK), dose limiting toxicity (DLT), maximum tolerated dose and recommended dose (RD) of the combination of sorafenib plus ifosfamide in patients with advanced sarcoma." | 5.19 | Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. ( Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM, 2014) |
| " Twenty-five histological subtypes were included: most frequent were leiomyosarcoma (n=48, receiving sorafenib in 63%, and sunitinib in 27%), GIST (n=39, receiving sorafenib in 79%), and angiosarcoma (n=18, receiving sorafenib in 78%)." | 5.19 | The off-label use of targeted therapies in sarcomas: the OUTC'S program. ( Adenis, A; Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Cassier, P; Chaigneau, L; Chevreau, C; Collard, O; Cropet, C; Cupissol, D; Duffaud, F; Eberst, L; Gentet, JC; Le Cesne, A; Marec-Berard, P; Pautier, P; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Thyss, A, 2014) |
| "We conducted a phase I trial of the addition of sorafenib to a chemoradiotherapy regimen in patients with high-risk (intermediate/high grade, >5 cm) extremity soft tissue sarcoma undergoing limb salvage surgery." | 5.17 | Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. ( Afzal, A; Beckett, BR; Doung, YC; Hayden, JB; Holtorf, ML; Huang, W; Hung, AY; Jones, RL; Mansoor, A; Meyer, JM; Mori, M; Perlewitz, KS; Pommier, RF; Rodler, ET; Ryan, CW; Tudorica, A; Vetto, JT; Woodward, WJ, 2013) |
| "To report on the anti-tumour activity and toxicity of sorafenib combined with dacarbazine in patients with pre-treated advanced soft tissue sarcoma (STSs)." | 5.17 | Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. ( Dei Tos, AP; Del Vescovo, R; Frezza, AM; Santini, D; Schiavon, G; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB, 2013) |
| "Sorafenib appears to be a promising option in leiomyosarcoma patients." | 5.17 | Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. ( Basso, U; Bertuzzi, A; Boglione, A; Comandone, A; De Sanctis, R; Giordano, L; Lutman, FR; Marcon, I; Santoro, A; Soto Parra, H; Stroppa, E, 2013) |
| "The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease." | 5.16 | Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. ( Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M, 2012) |
| "Phase II multi-disease randomized discontinuation trial to assess the safety and efficacy of sorafenib including patients with advanced soft tissue sarcoma (STS)." | 5.15 | Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. ( Cupit, L; Flaherty, KT; Judson, IR; Kaye, SB; O'Dwyer, PJ; Pacey, S; Ratain, MJ; Rowinsky, EK; Xia, C, 2011) |
| "PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic sarcoma." | 5.14 | Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. ( Antonescu, CR; Blachère, NE; Brockstein, B; Cooney, MM; D'Adamo, DR; Edgar, MA; Elias, AD; Hensley, ML; Keohan, ML; Kraft, AS; Livingston, MB; Maki, RG; Mita, MM; Qin, LX; Saulle, M; Schuetze, SM; Schwartz, GK; Schwartz, LH; Takimoto, CH; Undevia, SD, 2009) |
| "We exposed human sarcoma cell lines to sorafenib, regorafenib, and pazopanib and assessed cell viability and expression of CSC markers (ALDH, CD24, CD44, and CD133)." | 3.80 | Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. ( Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J, 2014) |
| "We have analyzed the expression of SIRT1 and SIRT2 in a series of pediatric sarcoma tumor cell lines and normal cells, and we have evaluated the activity of the sirtuin inhibitor and p53 activator tenovin-6 (Tv6) in synovial sarcoma and rhabdomyosarcoma cell lines." | 3.80 | SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth. ( Brodin, B; D'Arcy, P; de Milito, A; Kis, L; Lain, S; Ma, L; Maruwge, W; Pellegrini, P; Strambi, A, 2014) |
| "Sorafenib was continued during the entire period of RT as tolerated." | 2.79 | Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity. ( Borys, D; Boutin, RD; Canter, RJ; Christensen, SD; Lee, LY; Li, CS; Monjazeb, AM; Olusanya, A; Tamurian, RM, 2014) |
| "Sorafenib is a multi-targeted tyrosine kinase inhibitor with therapeutic efficacy in several malignancies." | 2.77 | Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). ( Ancukiewicz, M; Boucher, Y; Demetri, GD; Duda, DG; Eder, JP; Jain, RK; Lahdenranta, J; Morgan, JA; Quek, R; Raut, CP, 2012) |
| "Both the soft tissue sarcomas and the neuroendocrine tumors are rare diseases." | 2.52 | [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor]. ( Kato, S, 2015) |
| "Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin." | 2.50 | Emerging therapeutic targets for synovial sarcoma. ( Ferrari, S; Paioli, A; Palmerini, E, 2014) |
| "Testing agents in cancers with multiple disease subtypes, in which the activity of a new treatment may vary between subtypes, presents statistical and logistical challenges." | 1.35 | Multiple Histology Phase II Trials. ( Crowley, J; Leblanc, M; Rankin, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.34) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 20 (68.97) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martín-Liberal, J | 1 |
| López-Pousa, A | 1 |
| Broto, JM | 1 |
| Cubedo, R | 1 |
| Gallego, O | 1 |
| Brendel, E | 1 |
| Tirado, OM | 1 |
| del Muro, XG | 1 |
| Meyer, JM | 1 |
| Perlewitz, KS | 1 |
| Hayden, JB | 1 |
| Doung, YC | 1 |
| Hung, AY | 1 |
| Vetto, JT | 1 |
| Pommier, RF | 1 |
| Mansoor, A | 1 |
| Beckett, BR | 1 |
| Tudorica, A | 1 |
| Mori, M | 1 |
| Holtorf, ML | 1 |
| Afzal, A | 1 |
| Woodward, WJ | 1 |
| Rodler, ET | 1 |
| Jones, RL | 1 |
| Huang, W | 1 |
| Ryan, CW | 2 |
| Subbiah, V | 1 |
| Westin, SN | 1 |
| Wang, K | 1 |
| Araujo, D | 1 |
| Wang, WL | 1 |
| Miller, VA | 1 |
| Ross, JS | 1 |
| Stephens, PJ | 1 |
| Palmer, GA | 1 |
| Ali, SM | 1 |
| Canter, RJ | 2 |
| Borys, D | 2 |
| Olusanya, A | 1 |
| Li, CS | 2 |
| Lee, LY | 1 |
| Boutin, RD | 1 |
| Christensen, SD | 1 |
| Tamurian, RM | 1 |
| Monjazeb, AM | 3 |
| Palmerini, E | 1 |
| Paioli, A | 1 |
| Ferrari, S | 1 |
| Huber, K | 1 |
| Feuchtinger, A | 1 |
| Borgmann, DM | 1 |
| Li, Z | 1 |
| Aichler, M | 1 |
| Hauck, SM | 1 |
| Zitzelsberger, H | 1 |
| Schwaiger, M | 1 |
| Keller, U | 1 |
| Walch, A | 1 |
| Ames, E | 1 |
| Mac, S | 1 |
| Grossenbacher, SK | 1 |
| Chen, M | 1 |
| Smith, RC | 1 |
| Tellez, J | 1 |
| Sayers, TJ | 1 |
| Murphy, WJ | 1 |
| Wong, P | 1 |
| Houghton, P | 1 |
| Kirsch, DG | 1 |
| Finkelstein, SE | 1 |
| Xu-Welliver, M | 1 |
| Dicker, AP | 1 |
| Ahmed, M | 1 |
| Vikram, B | 1 |
| Teicher, BA | 1 |
| Coleman, CN | 1 |
| Machtay, M | 1 |
| Curran, WJ | 1 |
| Wang, D | 1 |
| Ma, L | 1 |
| Maruwge, W | 1 |
| Strambi, A | 1 |
| D'Arcy, P | 1 |
| Pellegrini, P | 1 |
| Kis, L | 1 |
| de Milito, A | 1 |
| Lain, S | 1 |
| Brodin, B | 1 |
| Eberst, L | 1 |
| Cropet, C | 1 |
| Le Cesne, A | 2 |
| Pautier, P | 1 |
| Penel, N | 2 |
| Adenis, A | 1 |
| Chevreau, C | 2 |
| Bay, JO | 1 |
| Collard, O | 2 |
| Cupissol, D | 1 |
| Duffaud, F | 2 |
| Gentet, JC | 1 |
| Piperno-Neumann, S | 1 |
| Marec-Berard, P | 1 |
| Bompas, E | 2 |
| Thyss, A | 1 |
| Chaigneau, L | 1 |
| Cassier, P | 1 |
| Bertucci, F | 2 |
| Blay, JY | 2 |
| Ray-Coquard, I | 1 |
| Semenova, AI | 1 |
| Protsenko, SA | 1 |
| Komarov, YI | 1 |
| Teletaeva, GM | 1 |
| Latipova, DH | 1 |
| Novik, AV | 1 |
| Tresch-Bruneel, E | 1 |
| Lebellec, L | 1 |
| Laurence, V | 1 |
| Saada-Bouzid, E | 1 |
| Isambert, N | 1 |
| Amela, EY | 1 |
| Salas, S | 2 |
| Italiano, A | 1 |
| Clisant, S | 1 |
| Kato, S | 1 |
| Maki, RG | 1 |
| D'Adamo, DR | 1 |
| Keohan, ML | 1 |
| Saulle, M | 1 |
| Schuetze, SM | 1 |
| Undevia, SD | 1 |
| Livingston, MB | 1 |
| Cooney, MM | 1 |
| Hensley, ML | 1 |
| Mita, MM | 1 |
| Takimoto, CH | 1 |
| Kraft, AS | 1 |
| Elias, AD | 1 |
| Brockstein, B | 1 |
| Blachère, NE | 1 |
| Edgar, MA | 1 |
| Schwartz, LH | 1 |
| Qin, LX | 1 |
| Antonescu, CR | 1 |
| Schwartz, GK | 1 |
| Leblanc, M | 1 |
| Rankin, C | 2 |
| Crowley, J | 1 |
| Pacey, S | 1 |
| Ratain, MJ | 1 |
| Flaherty, KT | 1 |
| Kaye, SB | 1 |
| Cupit, L | 1 |
| Rowinsky, EK | 1 |
| Xia, C | 1 |
| O'Dwyer, PJ | 1 |
| Judson, IR | 1 |
| Huynh, T | 1 |
| Deville, JL | 1 |
| Lekili, M | 1 |
| Muezzinoglu, T | 1 |
| Nese, N | 1 |
| Temeltas, G | 1 |
| von Mehren, M | 1 |
| Goldblum, JR | 1 |
| Demetri, GD | 2 |
| Bramwell, V | 1 |
| Borden, E | 1 |
| Raut, CP | 1 |
| Boucher, Y | 1 |
| Duda, DG | 1 |
| Morgan, JA | 1 |
| Quek, R | 1 |
| Ancukiewicz, M | 1 |
| Lahdenranta, J | 1 |
| Eder, JP | 1 |
| Jain, RK | 1 |
| Vincenzi, B | 1 |
| Silletta, M | 1 |
| Schiavon, G | 1 |
| Frezza, AM | 1 |
| Del Vescovo, R | 1 |
| Zobel, BB | 1 |
| Santini, D | 1 |
| Dei Tos, AP | 1 |
| Tonini, G | 1 |
| Santoro, A | 1 |
| Comandone, A | 1 |
| Basso, U | 1 |
| Soto Parra, H | 1 |
| De Sanctis, R | 1 |
| Stroppa, E | 1 |
| Marcon, I | 1 |
| Giordano, L | 1 |
| Lutman, FR | 1 |
| Boglione, A | 1 |
| Bertuzzi, A | 1 |
| MATSUYAMA, M | 1 |
| MAEKAWA, A | 1 |
| NAGAYO, T | 1 |
| RAIMONDI, L | 1 |
| PRINA, C | 1 |
| ROVETA, G | 1 |
| SCHMIDT, CG | 1 |
| Strumberg, D | 1 |
| Masunaga, S | 1 |
| Ono, K | 1 |
| Abe, M | 1 |
| Stüben, G | 1 |
| Stuschke, M | 1 |
| Knühmann, K | 1 |
| Horsman, MR | 1 |
| Sack, H | 1 |
| Honess, DJ | 1 |
| Hill, SA | 1 |
| Collingridge, DR | 1 |
| Edwards, B | 1 |
| Brauers, G | 1 |
| Powell, NA | 1 |
| Chaplin, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer[NCT01187199] | Phase 1 | 278 participants (Anticipated) | Interventional | 2010-08-19 | Active, not recruiting | ||
| Phase I/II Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall[NCT00864032] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy[NCT01308034] | Phase 1 | 25 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma[NCT00330421] | Phase 2 | 15 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of dose limiting toxicities and number with adverse events.~Dose-escalation schedule comprising 6 to 12 patients (see schema). This sample size is based on a traditional 3+3 cohort design with escalating doses of sorafenib in combination with 50 Gy of conformal radiotherapy delivered in 25 fractions (200 cGy per fraction). Based on preclinical data regarding the radiobiology of sorafenib,33, 36 sorafenib will be initiated at a dose of 200 mg twice daily, followed by 200 mg Q AM/400 mg Q PM for the 2nd cohort, followed by 400 mg bid for the 3rd cohort. Since 400 mg bid is the well established MTD for sorafenib monotherapy in patients with renal cell carcinoma and hepatocellular carcinoma, the dose will not be escalated above this level even if DLT is not observed. Dose level escalation will be determined based on DLTs observed from initiation of sorafenib/RT until time of surgery." (NCT00864032)
Timeframe: Approximately 12 weeks
| Intervention | DLTs (Number) |
|---|---|
| Sorafenib 200/200 | 0 |
| Sorafenib 200/400 | 2 |
Paired comparison made using a Wilcoxon signed rank test with one-sided type I error of 5%. (NCT00330421)
Timeframe: Baseline to up to 1 month post-treatment
| Intervention | mm Hg (Mean) |
|---|---|
| Group II (Metastatic or Inoperable Sarcomas) | 4.25 |
5 reviews available for niacinamide and Sarcoma
| Article | Year |
|---|---|
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; | 2014 |
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2014 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestin | 2015 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal | 2010 |
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2005 |
12 trials available for niacinamide and Sarcoma
| Article | Year |
|---|---|
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Prol | 2014 |
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.
Topics: Adult; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Magnetic Resonance Imaging; Mal | 2013 |
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
Topics: Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Extremities; Female; Follow-Up Studies; Human | 2014 |
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Drug Delive | 2014 |
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chordoma; Female; Follow-Up Studies; France; | 2015 |
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free S | 2009 |
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Demography; Female; Humans; Male; Middle Aged | 2011 |
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Leiomyosar | 2012 |
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Benzenesulfonates; Bioma | 2012 |
Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fem | 2013 |
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Disease-Free Survival; Female; Humans; Leiomyosarcom | 2013 |
12 other studies available for niacinamide and Sarcoma
| Article | Year |
|---|---|
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; | 2014 |
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; C | 2014 |
SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.
Topics: Acetylation; Animals; Autophagy; Benzamides; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferat | 2014 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2015 |
Multiple Histology Phase II Trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase II as Topic; Computer Simulation; H | 2009 |
Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Ma | 2010 |
Inhibiting effect of nicotinamide and diphosphopyridine nucleotide on the methylcholanthrene sarcoma in rats.
Topics: Animals; Coenzymes; Methylcholanthrene; NAD; Neoplasms; Niacin; Niacinamide; Nicotinic Acids; Rats; | 1961 |
[ACTION OF WATER-SOLUBLE COMPLEXES OF 3,4-BENZOPYRENE ON TUMOR ASCITES FLUIDS. ELECTROPHORETIC STUDIES].
Topics: Animals; Ascites; Benzo(a)pyrene; Benzopyrenes; Carbohydrates; Carcinoma, Ehrlich Tumor; Electrophor | 1963 |
EFFECT OF CARCINOPHILIN ON DPN-SYNTHESIS AND GLYCOLYSIS OF TUMOR CELLS.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Anti-Bacterial Agents; Antibiotics, Antitubercular; Ant | 1964 |
The detection and modification of the hypoxic fraction in quiescent cell populations in murine solid tumours.
Topics: Animals; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Survival; Female; Mice; Mice, Inbred BALB C; | 1993 |
The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies.
Topics: Administration, Inhalation; Animals; Carbon Dioxide; Cell Hypoxia; Drug Combinations; Glioblastoma; | 1998 |
Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo.
Topics: Adenocarcinoma; Animals; Carbon Dioxide; Carcinoma; Cell Hypoxia; Colonic Neoplasms; Contrast Media; | 1998 |